Bring your Treatment Resistant Schizophrenia patients out of themselves

Welcome to Clozaril® Connect, a support programme to help clinicians diagnose, treat, and manage patients with Treatment Resistant Schizophrenia (TRS) who may benefit from clozapine – the only treatment recommended by the National Institute for Health and Care Excellence (NICE) for TRS.

Getting to know TRS

As part of the support offered by the Clozaril® Connect programme, this website provides healthcare professionals (HCPs) with a useful hub of information on all aspects of schizophrenia, with a special emphasis on those patients who fail to respond to initial treatments: TRS patients, and how Clozaril® (clozapine) can help these patients.

CLZ-2022-0108  May 2023

This website is owned and managed by Viatris.

This website is intended for UK and Ireland healthcare professionals only.

Clozaril is indicated in treatment-resistant schizophrenic patients and in schizophrenia patients who have severe, untreatable neurological adverse reactions to other antipsychotic agents, including atypical antipsychotics.

Treatment resistance is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two different antipsychotic agents, including an atypical antipsychotic agent, prescribed for adequate duration.

Clozaril is also indicated in psychotic disorders occurring during the course of Parkinson's disease, in cases where standard treatment has failed.

© Copyright 2023 Viatris Inc. All rights reserved.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)

Reporting of adverse reactions:

UK: Please continue to report suspected side effects to the MHRA through the Yellow Card Scheme. Please report all suspected side effects that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason. It is easiest and quickest to report side effects online via the Yellow Card website – https://yellowcard.mhra.gov.uk/ or via the Yellow Card app available from the Apple App Store or Google Play Store. Alternatively, prepaid Yellow Cards for reporting are available by writing to FREEPOST YELLOW CARD (no other address details necessary); by emailing yellowcard@mhra.gov.uk; at the back of the British National Formulary (BNF); by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789; or by downloading and printing a form from the Yellow Card website.

Ireland: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system HPRA Pharmacovigilance, Website: www.hpra.ie.

Adverse reactions/events should also be reported to the marketing authorisation holder at email address: CPMS@Viatris.com

Restricted access

The website you are trying to access is designed for healthcare professionals only - the content is not designed for the general public.

Are you a healthcare professional based in UK or Ireland?

YES
NO

hcp popup title

Viatris Connect is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Viatris Connect today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.

REGISTER NOW